Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $6.83
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 28, 26 | HC Wainwright & Co. |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 16, 26 | Yonehiro Grant | officer: Chief Operating Officer | S-Sale | 1,417 @ $3.77 | $5.35K |
Daily · Wilder smoothing
| maintain |
| Buy |
| Buy |
| Mar 13, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 15, 25 | Lake Street | maintain | Buy | Buy |
| May 13, 25 | Stifel | maintain | Hold | Hold |
| Mar 25, 25 | HC Wainwright & Co. | maintain | Neutral | Neutral |
| Mar 25, 25 | Stifel | maintain | Hold | Hold |
| May 15, 24 | Guggenheim | downgrade | Buy | Neutral |
| May 15, 24 | Stifel | downgrade | Buy | Hold |
| May 15, 24 | Leerink Partners | downgrade | Outperform | Market Perform |
| Sep 17, 26 |
| Yonehiro Grant |
| officer: Chief Operating Officer |
| S-Sale |
| 4,909 @ $3.32 |
| $16.29K |
| Sep 18, 26 | Yonehiro Grant | officer: Chief Operating Officer | S-Sale | 6,850 @ $3.24 | $22.17K |
| Sep 16, 26 | Nemec Sarah | officer: Senior VP, Finance and PAO | S-Sale | 843 @ $3.77 | $3.18K |
| Sep 17, 26 | Nemec Sarah | officer: Senior VP, Finance and PAO | S-Sale | 2,922 @ $3.32 | $9.70K |
| Sep 18, 26 | Nemec Sarah | officer: Senior VP, Finance and PAO | S-Sale | 4,077 @ $3.24 | $13.19K |
| Jun 5, 26 | Nemec Sarah | officer: Senior VP, Finance and PAO | P-Purchase | 509 @ $3.88 | $1.97K |
| Sep 16, 26 | Quinn William P. | director, officer: President, CEO and CFO | S-Sale | 1,889 @ $3.77 | $7.13K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 82.21 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 66.39 | Oscillator | Neutral |
| Williams %R (14) | -21.59 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.35 (Hist 0.20) | Oscillator | Strong Buy |
| Average Directional Index (14) | 24.82 (+DI 58.3 / -DI 7.9) | Trend | Buy |
| EMA 20 | 4.23 | MA | Strong Buy |
| SMA 20 | 4.02 | MA | Strong Buy |
| EMA 50 | 4.00 | MA | Strong Buy |
| SMA 50 | 3.82 | MA | Strong Buy |
| SMA 200 | 4.50 | MA | Strong Buy |
Stock news · updated daily
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned.
Shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.20 and traded as high as $4.48. Bolt Biotherapeutics shares last traded at $4.14, with a volume of 34,467 shares trading hands. Wall
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.23 and traded as low as $3.45. Bolt Biotherapeutics shares last traded at $3.53, with a volume of 23,259 shares changing hands. Wall Street Analyst Weigh In Separately,
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) VP Sarah Nemec sold 4,077 shares of Bolt Biotherapeutics stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a total value of $13,209.48. Following the completion of the transaction, the vice president owned 17,082 shares of the
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) COO Grant Yonehiro sold 4,909 shares of the firm's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $3.32, for a total transaction of $16,297.88. Following the completion of the transaction, the chief operating officer directly owned
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -3.39 | -4.57 | Miss -34.8% | $5.00K |
| May 12, 2026 | -2.85 | -4.31 | Miss -51.2% | $26.00K |
| Mar 12, 2026 | -4.30 | -3.84 | Beat 10.7% | $2.50M |
| Nov 12, 2025 | -5.07 | -3.72 | Beat 26.6% | $2.17M |
| Aug 14, 2025 | -6.40 | -4.46 | Beat 30.3% | $1.80M |
| May 12, 2025 | -6.80 | -5.80 | Beat 14.7% | $1.22M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 23, 2026 | 2026-10-23 10:31:29 | View |
| 8-K | Oct 6, 2026 | 2026-10-06 16:07:53 | View |
| 4 | Sep 21, 2026 | 2026-09-21 18:05:24 | View |
| 4 | Sep 21, 2026 | 2026-09-21 18:04:37 | View |
| 4 | Sep 21, 2026 | 2026-09-21 18:03:56 | View |
| SC 13G | Aug 13, 2026 | 2026-08-13 16:20:20 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:06:38 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:05:15 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:15:03 | View |
| 4 | Jun 11, 2026 | 2026-06-11 16:14:03 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BOLT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.4x | -13.1x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.4x | EPS est. -17.89 | In line |
| Price / Book | 0.9x | 0.4x | Elevated |
| Price / Sales | 2.8x | 32.7x | Discount |
| EV / EBITDA | -0.8x | -0.9x | In line |
| Return on equity | -126.2% | — | Weak |
| Gross margin | 95.7% | -1516.3% | Below hist. |
| Debt / Equity | 1.71 | 0.34 | Levered |
| Piotroski / Altman Z | 2/9 | Z -18.19 | Distress |
Discounted cash flow model